- Home
- ELVN vs MFA Comparison
ELVN vs MFA Comparison
Compare ELVN & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- MFA
- Stock Information
- Founded
- ELVN 2016
- MFA 1997
- Country
- ELVN United States
- MFA United States
- Employees
- ELVN N/A
- MFA N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- MFA Real Estate Investment Trusts
- Sector
- ELVN Health Care
- MFA Real Estate
- Exchange
- ELVN Nasdaq
- MFA Nasdaq
- Market Cap
- ELVN 1.2B
- MFA 1.0B
- IPO Year
- ELVN 2020
- MFA N/A
- Fundamental
- Price
- ELVN $19.93
- MFA $9.73
- Analyst Decision
- ELVN Strong Buy
- MFA Buy
- Analyst Count
- ELVN 5
- MFA 8
- Target Price
- ELVN $41.20
- MFA $11.50
- AVG Volume (30 Days)
- ELVN 503.5K
- MFA 1.1M
- Earning Date
- ELVN 11-12-2025
- MFA 11-05-2025
- Dividend Yield
- ELVN N/A
- MFA 14.79%
- EPS Growth
- ELVN N/A
- MFA 41.64
- EPS
- ELVN N/A
- MFA 0.88
- Revenue
- ELVN N/A
- MFA $284,489,000.00
- Revenue This Year
- ELVN N/A
- MFA N/A
- Revenue Next Year
- ELVN $20.05
- MFA $16.86
- P/E Ratio
- ELVN N/A
- MFA $11.06
- Revenue Growth
- ELVN N/A
- MFA 9.37
- 52 Week Low
- ELVN $13.30
- MFA $7.85
- 52 Week High
- ELVN $30.03
- MFA $13.45
- Technical
- Relative Strength Index (RSI)
- ELVN 51.15
- MFA 41.50
- Support Level
- ELVN $18.01
- MFA $10.15
- Resistance Level
- ELVN $20.30
- MFA $10.57
- Average True Range (ATR)
- ELVN 1.13
- MFA 0.19
- MACD
- ELVN -0.08
- MFA -0.07
- Stochastic Oscillator
- ELVN 58.21
- MFA 6.67
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.